In 19 patients with previously treated RET fusion-positive thyroid cancer, selpercatinib showed a 79% objective response and 64% of 1-year PFS rate, with a low discontinuous rate (2%, 12 out of 531) due to adverse events (Wirth et al., 2020). This evidence concerns the gene RET and thyroid cancer.